Company Description
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases.
It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.
It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis.
It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand.
The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates.
The company was founded in 1998 and is based in Florham Park, New Jersey.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 225 |
| CEO | Dr. Robert Joseph Hariri M.D., Ph.D. |
Contact Details
Address: 170 Park Ave Florham Park, New Jersey 07932 United States | |
| Phone | (908) 768-2170 |
| Website | celularity.com |
Stock Details
| Ticker Symbol | CELU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001752828 |
| CUSIP Number | 151190105 |
| ISIN Number | US1511902041 |
| Employer ID | 83-1702591 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert Joseph Hariri M.D., Ph.D. | Founder, Chief Executive Officer and Chairman |
| David C. Beers C.F.A. | Chief Financial Officer |
| John R. Haines | Senior EVice President, Global Manager and Chief Administrative Officer |
| Ramji Krishnan | Chief Technology Officer |
| Carlos Ramirez | SVice President of Investor Relations |
| Kyle Harold Fletcher Esq. | Executive Vice President, General Counsel and Chief Compliance Officer |
| Dr. Stephen A. Brigido D.P.M. | President of Degenerative Diseases |
| Dr. Adrian Kilcoyne M.B.A., M.D., M.P.H. | Executive Vice President, Chief Medical Officer and Head of Global Affairs, Patient Safety and Patient Affairs |
| Sharmila Koppisetti M.D. | Senior Vice President of Clinical Dev. Immunology and Drug Safety |
| Tim Wilk | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 15, 2024 | 8-K | Current Report |
| Feb 26, 2024 | 8-K | Current Report |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 12, 2024 | 8-K | Current Report |
| Feb 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 2, 2024 | DEF 14A | Other definitive proxy statements |
| Jan 23, 2024 | PRE 14A | Other preliminary proxy statements |
| Jan 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |